#VisualAbstract: Pazopanib does not improve disease-free survival post-metastasectomy for renal cell carcinoma patients

1. Pazopanib did not improve disease-free survival in post-metastasectomy renal cell carcinoma patients 2. There was a concerning trend favouring placebo when assessing overall survival, suggesting a negative impact of pazopanib. Evidence Rating Level: 1(Excellent) Study Rundown: The E2810 trial was a randomized, double-blind phase III trial assessing the impact of pazopanib on patients with metastatic renal cell